Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So ACAD's Rett breakthrough nets the company a 10% pop? Not a very impressive reaction by the market, especially since a month ago the sp was where it is now, around $21.50. Even taking into account ACAD's market cap is double AVXL's - making a big 'pop' more difficult to achieve - this doesn't bode particularly well for eventual mkt reception of Anavex Rett news, unless of course it is absolutely stunning. Hoping it is...
Reddit
Where's reddit when ya need 'em
Reviewing the sp’s for the year for our so-called competitors reveal that the primary four AD newsmakers (BIIB, SAVA, ANVS, and CRTX) took sound thrashings from their 2021 highs thru Friday 12/3, to the tune of around 45-80%. Anavex dropped around 39% from its closing high in June. 2/4/21 is the mystery date…no news IIRC, huge gap up at open, 116 million shares traded, double+ HOD, then total collapse to a mere 20% gain.
WTH happened on that day? Anyone on the board ever ferret out a reasonable explanation?
We've now made a round trip from where the fun began on 17mm shares in mid-June. Very disappointing.
Looks like the close of yet another week of blunt force trauma. I'm ready for a new season...this data is obviously too rich for me.
At least Biogen's arse-kicking continues unabated.
We need to see volume IMO. I agree with WallyP - still feels like range trading until we blast past our old high from 2/2021. I do think the jig is up for the amyloid crowd...these guys are still running the I-formation on 3rd-and-long. But, we (AVXL) are still one or two serious news events - ahem, cough, cough, RETT results, anyone? - from capturing the attention of Those That Count, giving us the immediate rocket shot to 35 or 40 (that sticks...volume!) that we have been waiting for for way too long.
Always appreciate your posted thoughts, Nidan.
Now faith is the substance of things hoped for, the evidence of things not seen.
Heb 11:1
Where my true faith lies...
Readouts coming, its still a data rich quarter until it isnt.
Seems to me Tred that it's not a data rich quarter until it is.
Considering the breadth and depth of the pipeline, I disagree. A Lexus would have us at 35 bucks, at least.
If you're new to AVXL, here's a bit of wisdom: nearly everything that this company does communications-wise is a complete fiasco. The veteran shareholders on this board are used to the process, kind of like an abused wife facing her drunken husband (again). We don't like it, but we accept the broken bones just the same.
Five bucks in less than seven days...pretty darn impressive.
Meanwhile, the market telegraphs its thoughts on AVXL's anticipated Wednesday dump.
Ugh.
As Dylan once noted - 'the hour is getting late...'
DisOrder in the Court.
-------------------------
One of my favorites
Try reading my original post about ACIU getting punished after lunch. Seems like someone peed in your cornflakes.
Not wrong. ACIU up only 24% pm after being up 78% at open. Simple math.
ACIU given appropriate after-lunch treatment by the market after that lukewarm bit of news.
Waiting patiently, George.
Normal reaction to a patent PR would be a 5% hit.
Or they can do nothing and see what happens.
You're quoting from Page 1 of the Bureaucrat's Handbook I see.
SAVA is now officially Sham (in the backstretch at Belmont Park) to AVXL's Secretariat. ANVS and BIIB 40-50 lengths behind.
By selling photographic supplies?
Sheesh.
I never said anything about 'no drug approval.'
I don't want any news anymore. Just revenue.
Not the worst PR-day performance by AVXL...lol
We need some stinking revenue.
The 5% mid-day arse kick seems to be the first page of the cabal playbook. Give the ball to your best player...
When will FDA get fixed?
"...perhaps one day when the pigmen roam free..."
- Elaine Benes (1993)
We're a Rett/PDD company as far as the market is concerned, not an alz play. I don't agree but it's true.
At this moment that might not be a bad thing. Alzheimer's drug development in 2021 is apparently a big 0-for-2, with both at-bats looking more like embarrassments than legit drug trials. Mario Mendoza trying to hit Randy Johnson in his prime.
Might be best for AVXL to establish credibility through display of unsinkable Rett and PD readouts/NDAs, then officially tackle the AD monster when some of the Shkreli-like mayhem has subsided.
If we were really linked to SAVA's credibility we'd be at 50 bucks.
I had seen the petition. What is not understandable to me at least is why AVXL stock gets hit, too. The petition is SAVA's problem.
Reason why down? AVXL's history has been whatever news hits the stock or the industry the stock goes down. No idea why.
SAVA down nearly 20% AH, AVXL -4.6%.
Agree. If we hold around 19.50 at close we'll have poked out of the downward channel that began end of June. MACD/Stochastics looking great, we should find a new (temporary) home in the low 20's.
I guess I'll have to hate Notre Dame just a bit less with that info on Parseghian's family. The FDA absolutely has to change its tune on rare, fatal disease treatment approaches...conservative and judicious is giving way to cruel and heartless with such conditions. When under near-term death sentence, risks to life with alternative treatments approaches ZERO.
Nice trade, btw.
This petition request hit my email this morning, for a rare disease I'd never heard of - Niemann Pick Type C (NPC). We need a re-tooled FDA.
----------------------------------
(boldface mine)
We need your help to save our kids fighting fatal NPC.
We are patients and parents of children and adults living with an ultra-rare and fatal disease called Niemann Pick Type C (NPC). We are in a fight for our lives to get new therapies approved by the US FDA, and we need your help. The clock is ticking, and every day that goes by NPC is damaging us and our children.
NPC is like Alzheimers, Parkinson’s and ALS rolled into one, except even more rare, causing extreme declines in how we move, talk, think, and even eat - pretty much everything. This disease occurs across all ages - and, horrifically, will frequently first show up in young children, even babies.
There is no cure or approved therapy here in the United States...but there are several medicines that have been in development and used experimentally by patients for years and years. Patients AND our treating doctors see the tremendous benefits of these medicines in helping us keep the ability to walk, talk, play and swallow. This is a BIG deal. It’s life saving.
Heartbreakingly, however, the FDA has become a barrier to helping these therapies cross the finish line - requiring multiple placebo control trials, not listening to our expert clinicians, discounting patient benefits, and not understanding our ultra rare variable and fatal disease. And we have had enough. It is time for regulators to:
Think differently about treatments for NPC and the multiple clinical trials that have demonstrated how these therapies have benefits that outweigh their risks;
Listen to patients and families about their needs; and
Act on expert guidance from doctors and researchers across the country who have studied this disease and treated patients for decades and recommend approval of investigational therapies.
Our community has met many times with the decision makers at FDA over the years to discuss the desperate need for approved therapies - including as recently as August 3, 2021. And while government officials say they “hear us,” there is no sign of movement or action to advance our cause. In fact, FDA has tried to keep new patients from accessing these experimental medications by erecting hurdles to early access programs and denying requests for approvals.
We need the following changes to occur immediately:
The FDA must lift all barriers that have blocked new patients from participating in programs that allow access to experimental medications, or have created uncertainties for patients currently receiving these medications. This includes removing any barriers to receiving drugs known as adrabetadex and arimoclomol.
The FDA must evaluate medications to treat NPC with the knowledge that NPC is ultra-rare, degenerative and fatal, and use regulatory flexibility when reviewing clinical trial data that shows meaningful improvements, particularly given the known natural history of this fatal disease.
The FDA must work with the scientific and patient community to design trials that are feasible and meaningful and that the trials do not put patients in harm’s way.
Add your signature to tell the FDA that it must address the needs of those with NPC by approving medicines and increasing access to existing medicines. Please tell FDA, don’t give up on NPC - for the patients of tomorrow AND those alive today. Please help save our lives. Thank you!!